Triple-negative breast cancer (TNBC) is characterized by the lack of expression of estrogen receptor (ER) and progesterone receptor (PR) and the absence of amplification of ERBB2. It encompasses a large spectrum of breast malignancies and is highly heterogeneous in terms of histology, molecular features, and clinical behavior1. Here, ESR1 is linked to triple-negative breast carcinoma.